Latest Insider Transactions at Akebia Therapeutics, Inc. (AKBA)
This section provides a real-time view of insider transactions for Akebia Therapeutics, Inc. (AKBA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akebia Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akebia Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2021
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,211
-0.45%
|
$3,633
$3.4 P/Share
|
|
Apr 01
2021
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,060
-0.39%
|
$3,180
$3.4 P/Share
|
|
Apr 01
2021
|
David A Spellman SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
790
-1.02%
|
$2,370
$3.4 P/Share
|
|
Apr 01
2021
|
Dell Faulkingham SVP, CCO |
SELL
Open market or private sale
|
Direct |
952
-0.69%
|
$2,856
$3.4 P/Share
|
|
Mar 16
2021
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,400
+5.71%
|
-
|
|
Mar 16
2021
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
39,520
+3.31%
|
-
|
|
Mar 16
2021
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,648
+4.18%
|
-
|
|
Mar 16
2021
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,192
+3.59%
|
-
|
|
Mar 16
2021
|
Dell Faulkingham SVP, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
9,152
+6.22%
|
-
|
|
Mar 16
2021
|
David A Spellman SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
7,592
+8.91%
|
-
|
|
Mar 01
2021
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,558
-4.47%
|
$22,674
$3.4 P/Share
|
|
Mar 01
2021
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
14,547
-2.73%
|
$43,641
$3.4 P/Share
|
|
Mar 01
2021
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
14,285
-2.61%
|
$42,855
$3.4 P/Share
|
|
Mar 01
2021
|
Dell Faulkingham SVP, CCO |
SELL
Open market or private sale
|
Direct |
6,749
-4.98%
|
$20,247
$3.4 P/Share
|
|
Mar 01
2021
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
49,990
-2.17%
|
$149,970
$3.4 P/Share
|
|
Feb 26
2021
|
David A Spellman SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+50.0%
|
-
|
|
Feb 26
2021
|
Violetta Cotreau SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+40.06%
|
-
|
|
Feb 26
2021
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+29.29%
|
-
|
|
Feb 26
2021
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,000
+18.69%
|
-
|
|
Feb 26
2021
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,000
+18.26%
|
-
|
|
Feb 26
2021
|
Dell Faulkingham SVP, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
62,000
+31.38%
|
-
|
|
Feb 26
2021
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
237,400
+16.91%
|
-
|